No Data
Australian and Chinese Endoscopy: 2024 Annual Results Forecast
2024 Annual Results Forecast
Aohua Endoscopy (688212.SH): Net profit for 2024 is expected to decline by 59.59% to 72.81%.
Gelonghui, January 22nd丨Aohua Endoscopy (688212.SH) announced the performance forecast for the fiscal year 2024, expecting a net income attributable to the owners of the parent company to be between 15.73 million yuan and 23.38 million yuan. Compared to the same period last year, this represents a decrease of 34.4744 million yuan to 42.1244 million yuan, with a year-on-year decline of 59.59% to 72.81%. For this reporting period, it is expected that the net income attributable to the owners of the parent company, after deducting non-recurring gains and losses, will be between -12.74 million yuan and -5.09 million yuan. During the reporting period, the company continued to strengthen its marketing efforts.
Shanghai Aohua Photoelectricity Endoscope (SHSE:688212) Has A Pretty Healthy Balance Sheet
Aohua Endoscopy (688212.SH): Shareholder Appalachian has cumulatively reduced its shareholding by 1.42%.
On November 14, Gelonghui reported that Auhua Endoscope (688212.SH) announced that the company received a notice from its shareholder Appalachian on November 13, 2024. As of the date of this announcement, Appalachian has reduced its shareholding by a total of 1,914,722 shares through centralized bidding and block trading, accounting for 1.42% of the company's total share capital. This shareholding reduction plan has been completed.
Australia China Endoscopy (688212.SH) 41.8228 million shares of restricted shares will be listed for trading starting November 15th.
Aohua Endoscopy (688212.SH) announced that the restricted shares to be listed for the first time are part of the company's initial public offering...
There's Been No Shortage Of Growth Recently For Shanghai Aohua Photoelectricity Endoscope's (SHSE:688212) Returns On Capital
